Qlife Holding AB (publ) (QLIFE.ST) Research

Operating as a medical technology firm, Qlife Holding AB (publ) specializes in the production and distribution of in-vitro diagnostic instruments and their associated chemical reagents. Their flagship offering is the Egoo.Health Platform, a comprehensive system comprising a measuring device, single-use test capsules, and integrated software. This innovative platform facilitates the detection of various biomarkers or viral agents, with each capsule tailored for a distinct diagnostic purpose. The range of supported biomarkers encompasses C-reactive protein for home-based monitoring, Phenylalanine (PHE) vital for managing Phenylketonuria (PKU) in patients, and a multiplex test designed to identify Sars-CoV-2 and Influenza, aiding in the detection of viral and bacterial infections. Established in 2019, Qlife's operations are headquartered in Helsingborg, Sweden.

Market snapshot

Symbol
QLIFE.ST
Price
$1.97
Day change
-3.29%
Market cap
$24.3M
P/E ratio
-0.87x
52-week range
1.205-5.74
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months

Peer companies

  • 2cureX AB (publ) (2CUREX.ST)
  • Aino Health AB (publ) (AINO.ST)
  • Chordate Medical Holding AB (publ) (CMH.ST)
  • Episurf Medical AB (publ) (EPIS-B.ST)
  • Fluicell AB (publ) (FLUI.ST)
  • Guard Therapeutics International AB (publ) (GUARD.ST)
  • ODI Pharma AB (ODI.ST)
  • Prostatype Genomics AB (publ) (PROGEN.ST)

Open Qlife Holding AB (publ) (QLIFE.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.